In the absence of early detection and initial treatment, prostate cancer often progresses to an advanced stage, frequently spreading to the bones and significantly impacting patients’ well-being and healthcare resources. Therefore, managing patients with prostate cancer that has spread to the bones often involves using bone-targeted medications like bisphosphonates and denosumab to enhance bone structure and minimize skeletal complications. Additionally, researchers are studying the tumor microenvironment and biomarkers to understand the mechanisms and potential treatment targets for bone metastases in prostate cancer. A literature search was conducted to identify clinical studies from 2013 to 2023 that focused on pain, performance status, or quality of life as primary outcomes. The analysis included details such as patient recruitment, prior palliative therapies, baseline characteristics, follow-up, and outcome reporting. The goal was to highlight the advancements and trends in bone metastasis research in prostate cancer over the past decade, with the aim of developing strategies to prevent and treat bone metastases and improve the quality of life and survival rates for prostate cancer patients.
若未能早期发现并接受初始治疗，前列腺癌常进展至晚期，并易发生骨转移，严重影响患者生活质量及医疗资源。因此，针对已发生骨转移的前列腺癌患者，临床常采用双膦酸盐类及地诺单抗等骨靶向药物以改善骨结构、减少骨骼相关并发症。同时，研究者正通过探究肿瘤微环境及生物标志物，以揭示前列腺癌骨转移的机制及潜在治疗靶点。本研究通过文献检索，筛选出2013年至2023年间以疼痛、体能状态或生活质量为主要结局指标的临床研究，并从患者招募情况、既往姑息治疗史、基线特征、随访及结局报告等方面进行综合分析，旨在总结近十年来前列腺癌骨转移研究领域的进展与趋势，以期为制定骨转移防治策略、提升患者生活质量和生存率提供参考。
肿瘤(癌症)患者之家